首页   >  
Ion Channel/Membrane Transporter
  >  
CFTR

所有产品分类

所有产品

信号通路

研究领域

天然产物

抗体

多肽

催化剂

杂质对照品

医药中间体

基础原料

CFTR

结构式 货号 产品名称 CAS号
Crinecerfont hydrochloride 结构式
BCP43623 Crinecerfont hydrochloride 321839-75-2
Crinecerfont is a potent and orally bioactive corticotropin-releasing factor 1 receptor (CRF1) antagonist (pKi values of 8.73 and 9.08 for human cloned or native CRF1 receptors, respectively) with 1000-fold selectivity for CRF1 over CRF2α receptor and CRF binding protein.
Elexacaftor R enantiomer 结构式
BCP35907 Elexacaftor R enantiomer 2229860-99-3
Elexacaftor (VX-445,) is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR). Elexacaftor (VX-445) facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface.
Deutivacaftor 结构式
BCP19794 Deutivacaftor 1413431-07-8
Deutivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) channel activator potentially for the treatment of cystic fibrosis.
Elexacaftor 结构式
BCP29711 Elexacaftor 2216712-66-0
Elexacaftor is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR). CFTR corrector 1 (compound 1) facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface.
FDL169 结构式
BCP30546 FDL169 1628416-28-3
FDL169 is an experimental therapy for cystic fibrosis (CF) that is being developed by Flatley Discovery Lab.
VX-659 结构式
BCP29456 VX-659 2204245-48-5
VX-659 is a CFTR protein inhibitor.
ABBV-2222 结构式
BCP25130 ABBV-2222 1918143-53-9
ABBV-2222, also known as GLPG2222, is a CFTR corrector being studied for the treatment of cystic fibrosis (CF).
VX-661 结构式
BCP07173 VX-661 1152311-62-0
VX-661 is a second F508del CFTR corrector and help CFTR protein reach the cell surface.
KM 11060 结构式
BCP17185 KM 11060 774549-97-2
KM11060 is a mutated F508del cystic fibrosis transmembrane conductance regulator (CFTR) corrector.
GLPG1837 结构式
BCP23611 GLPG1837 1654725-02-6
A potent, orally available CFTR potentiator with EC50 of 3 nM and 339 nM on F508del and G551D CFTR, respectively; shows enhanced efficacy on CFTR mutants harboring Class III mutations compared to Ivacaftor.
12下一页共 18 条记录 1 / 2 页 
2853530910